Cue Biopharma Statistics
Total Valuation
Cue Biopharma has a market cap or net worth of $95.90 million. The enterprise value is $81.90 million.
Important Dates
The last earnings date was Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cue Biopharma has 3.26 million shares outstanding. The number of shares has increased by 79.49% in one year.
| Current Share Class | 3.26M |
| Shares Outstanding | 3.26M |
| Shares Change (YoY) | +79.49% |
| Shares Change (QoQ) | +30.50% |
| Owned by Insiders (%) | 10.67% |
| Owned by Institutions (%) | 21.91% |
| Float | 2.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.93 |
| Forward PS | 13.51 |
| PB Ratio | 4.44 |
| P/TBV Ratio | 4.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.57, with a Debt / Equity ratio of 0.16.
| Current Ratio | 3.57 |
| Quick Ratio | 3.34 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -84.06 |
Financial Efficiency
Return on equity (ROE) is -138.52% and return on invested capital (ROIC) is -63.17%.
| Return on Equity (ROE) | -138.52% |
| Return on Assets (ROA) | -46.08% |
| Return on Invested Capital (ROIC) | -63.17% |
| Return on Capital Employed (ROCE) | -83.39% |
| Weighted Average Cost of Capital (WACC) | 17.82% |
| Revenue Per Employee | $1.13M |
| Profits Per Employee | -$673,207 |
| Employee Count | 29 |
| Asset Turnover | 1.23 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Cue Biopharma has paid $500,000 in taxes.
| Income Tax | 500,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +58.39% in the last 52 weeks. The beta is 2.55, so Cue Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 2.55 |
| 52-Week Price Change | +58.39% |
| 50-Day Moving Average | 19.79 |
| 200-Day Moving Average | 16.84 |
| Relative Strength Index (RSI) | 61.16 |
| Average Volume (20 Days) | 120,638 |
Short Selling Information
The latest short interest is 255,157, so 7.84% of the outstanding shares have been sold short.
| Short Interest | 255,157 |
| Short Previous Month | 288,887 |
| Short % of Shares Out | 7.84% |
| Short % of Float | 8.77% |
| Short Ratio (days to cover) | 0.19 |
Income Statement
In the last 12 months, Cue Biopharma had revenue of $32.73 million and -$19.52 million in losses. Loss per share was -$5.22.
| Revenue | 32.73M |
| Gross Profit | -2.11M |
| Operating Income | -19.59M |
| Pretax Income | -19.02M |
| Net Income | -19.52M |
| EBITDA | -18.16M |
| EBIT | -19.59M |
| Loss Per Share | -$5.22 |
Full Income StatementBalance Sheet
The company has $17.44 million in cash and $3.44 million in debt, with a net cash position of $14.00 million or $4.30 per share.
| Cash & Cash Equivalents | 17.44M |
| Total Debt | 3.44M |
| Net Cash | 14.00M |
| Net Cash Per Share | $4.30 |
| Equity (Book Value) | 21.61M |
| Book Value Per Share | 6.64 |
| Working Capital | 19.00M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$24.46 million and capital expenditures -$148,000, giving a free cash flow of -$24.61 million.
| Operating Cash Flow | -24.46M |
| Capital Expenditures | -148,000 |
| Depreciation & Amortization | 1.42M |
| Net Borrowing | -3.50M |
| Free Cash Flow | -24.61M |
| FCF Per Share | -$7.56 |
Full Cash Flow StatementMargins
Gross margin is -6.45%, with operating and profit margins of -59.84% and -59.65%.
| Gross Margin | -6.45% |
| Operating Margin | -59.84% |
| Pretax Margin | -58.12% |
| Profit Margin | -59.65% |
| EBITDA Margin | -55.49% |
| EBIT Margin | -59.84% |
| FCF Margin | n/a |
